- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Theses and Dissertations /
- Characterization of HsaC and HsaD, an oxygenase and...
Open Collections
UBC Theses and Dissertations
UBC Theses and Dissertations
Characterization of HsaC and HsaD, an oxygenase and a hydrolase in the cholesterol catabolic pathway of Mycobacterium tuberculosis Yam, Katherine
Abstract
Mycobacterium tuberculosis (Mtb) is the leading cause of mortality from bacterial infection. A cholesterol degradation pathway identified in Mtb is implicated in the pathogen’s survival in the host. This pathway includes an Fe(II)-containing extradiol dioxygenase, HsaC, and a meta-cleavage product (MCP) hydrolase, HsaD, which are predicted to catalyze the cleavage of DHSA (3,4-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione) and subsequent hydrolysis of DSHA (4,5-9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oic acid), respectively. HsaC and HsaD were expressed in E. coli, purified, and characterized. Substrates were obtained by biotransformation of cholesterol using a ΔhsaC mutant of Rhodococcus jostii RHA1. From steady-state kinetic studies, purified HsaC efficiently cleaved the proposed steroid metabolite, DHSA (kcat/Km = 15 ± 2 μM-¹s-¹), better than the biphenyl catechol, DHB, or a synthetic analogue, DHDS. Two halogenated substrates, 2’,6’-diCl DHB and 4-Cl DHDS, inactivated HsaC with partition coefficients < 50. Structures of HsaC:DHSA at 2.1 Å revealed predominantly bidentate binding of the catechol to the active site iron, as has been reported in similar enzymes. A high-throughput colorimetric assay was developed to screen for small molecular inhibitors of HsaC. 4-chloro-N-methyl-N-(4-[(4-methylpiperidin-1-yl) carbonyl] phenyl) benzene-1-sulfonamide and gedunin were identified as potent inhibitors of HsaC with Kic values of 450 ± 50 nM and 80 ± 10 nM, respectively. Purified HsaD had higher specificity for DSHA (kcat/Km = 3.3 ± 0.3 x 104 M-¹s-¹) than for the biphenyl metabolite and a synthetic analogue. The catalytically impaired S114A variant of HsaD bound DSHA with a Kd of 51 ± 2 μM. The S114A:DSHA species absorbed maximally at 456 nm, 60 nm red-shifted versus the DSHA enolate. Crystal structures of the S114A:DSHA complex at 1.9 Å identified the trapped intermediate as a 2-oxo, 6-oxido species. These data indicate that the catalytic serine catalyzes enol-to-keto tautomerization as well as C-C bond hydrolysis. While both ΔhsaC and ΔhsaD mutants of M. bovis BCG did not grow on cholesterol, the presence of an additional carbon source restored growth of the ΔhsaD mutant but only partial growth of the ΔhsaC mutant, likely due to toxic oxidized metabolites. Overall, the kinetic and structural characterization of these mycobacterial cholesterol-degrading enzymes provides novel insights into a disease of global importance.
Item Metadata
Title |
Characterization of HsaC and HsaD, an oxygenase and a hydrolase in the cholesterol catabolic pathway of Mycobacterium tuberculosis
|
Creator | |
Publisher |
University of British Columbia
|
Date Issued |
2011
|
Description |
Mycobacterium tuberculosis (Mtb) is the leading cause of mortality from bacterial infection. A cholesterol degradation pathway identified in Mtb is implicated in the pathogen’s survival in the host. This pathway includes an Fe(II)-containing extradiol dioxygenase, HsaC, and a meta-cleavage product (MCP) hydrolase, HsaD, which are predicted to catalyze the cleavage of DHSA (3,4-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione) and subsequent hydrolysis of DSHA (4,5-9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oic acid), respectively. HsaC and HsaD were expressed in E. coli, purified, and characterized. Substrates were obtained by biotransformation of cholesterol using a ΔhsaC mutant of Rhodococcus jostii RHA1. From steady-state kinetic studies, purified HsaC efficiently cleaved the proposed steroid metabolite, DHSA (kcat/Km = 15 ± 2 μM-¹s-¹), better than the biphenyl catechol, DHB, or a synthetic analogue, DHDS. Two halogenated substrates, 2’,6’-diCl DHB and 4-Cl DHDS, inactivated HsaC with partition coefficients < 50. Structures of HsaC:DHSA at 2.1 Å revealed predominantly bidentate binding of the catechol to the active site iron, as has been reported in similar enzymes. A high-throughput colorimetric assay was developed to screen for small molecular inhibitors of HsaC. 4-chloro-N-methyl-N-(4-[(4-methylpiperidin-1-yl) carbonyl] phenyl) benzene-1-sulfonamide and gedunin were identified as potent inhibitors of HsaC with Kic values of 450 ± 50 nM and 80 ± 10 nM, respectively. Purified HsaD had higher specificity for DSHA (kcat/Km = 3.3 ± 0.3 x 104 M-¹s-¹) than for the biphenyl metabolite and a synthetic analogue. The catalytically impaired S114A variant of HsaD bound DSHA with a Kd of 51 ± 2 μM. The S114A:DSHA species absorbed maximally at 456 nm, 60 nm red-shifted versus the DSHA enolate. Crystal structures of the S114A:DSHA complex at 1.9 Å identified the trapped intermediate as a 2-oxo, 6-oxido species. These data indicate that the catalytic serine catalyzes enol-to-keto tautomerization as well as C-C bond hydrolysis. While both ΔhsaC and ΔhsaD mutants of M. bovis BCG did not grow on cholesterol, the presence of an additional carbon source restored growth of the ΔhsaD mutant but only partial growth of the ΔhsaC mutant, likely due to toxic oxidized metabolites. Overall, the kinetic and structural characterization of these mycobacterial cholesterol-degrading enzymes provides novel insights into a disease of global importance.
|
Genre | |
Type | |
Language |
eng
|
Date Available |
2011-09-01
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution-NonCommercial-NoDerivatives 4.0 International
|
DOI |
10.14288/1.0072179
|
URI | |
Degree | |
Program | |
Affiliation | |
Degree Grantor |
University of British Columbia
|
Graduation Date |
2011-11
|
Campus | |
Scholarly Level |
Graduate
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International